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Abstract
EGFL7 is a secreted angiogenic factor, which in contrast to the well-known secreted angiogenic molecules VEGF and FGF-2,
is almost exclusively expressed by endothelial cells and may act in an autocrine fashion. Prior studies have shown EGFL7 to
mediate its angiogenic effects by interfering with the Notch pathway and/or via the intronic miR126. Less is known about its
effects on VEGF signaling. We wanted to investigate the role of epidermal growth factor-like domain 7 (EGFL7) in VEGF-
driven angiogenesis using an ex vivo Matrigel-embedded mouse eye cup assay and siRNA mediated knockdown of EGFL7
by siRNA. Our results suggested that VEGF-induced vascular tube formation was significantly impaired after siRNA
downregulation of EGFL7. In addition, knockdown of EGFL7 suppressed VEGF upregulation of phospho-Akt and phospho-
Erk(1/2) in endothelial cells, but did not alter VEGFR phosphorylation and neuropilin-1 protein expression or miR126
expression. Thus, in conclusion, EGFL7 is required for VEGF upregulation of the Akt/Erk (1/2) pathway during angiogenesis,
and may represent a new therapeutic target in diseases of pathological neovascularization.
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Introduction
Angiogenesis is an important biological process not only under
physiological conditions, but also in a variety of diseases including
cancer, rheumatoid arthritis [1–4], age-related macular degener-
ation [5], diabetic retinopathy [6], retinal vein occlusion [7], and
retinopathy of prematurity [8]. It is fundamental in many
biological processes including development, reproduction and
wound repair. With the exception of the vasculature of the female
reproductive system, the endothelium of the adult vasculature is
normally quiescent. The vasculature becomes activated and grows
new capillaries through angiogenesis in response to appropriate
stimuli (i.e., injury, atherosclerosis, tumor growth and metastasis,
arthritis). Under these conditions, angiogenesis is a highly
regulated process. The sprouting of vessels involves activation of
quiescent endothelial cells, proteolytic degradation of the extra-
cellular matrix, chemotactic migration, invasion into the sur-
rounding stroma, and endothelial cell proliferation and differen-
tiation [2,9–12]. Numerous inducers of angiogenesis have been
identified, including the members of the vascular endothelial
growth factor (VEGF) family, angiopoietins, transforming growth
factors (TGFs), platelet-derived growth factor (PDGF), tumor
necrosis factor alpha (TNF-a), interleukins, and members of the
fibroblast growth factor (FGF) family [13,14].
Recently, the novel angiogenic factor epidermal growth factor
(EGF)-like domain 7 (EGFL7) has been described [15]. EGFL7 is
a 41-kDa secreted angiogenic factor with high homology among
vertebrates. In unique contrast to the well-known secreted
angiogenic molecules VEGF and FGF-2, which are mainly
produced by non-endothelial cells, EGFL7 is almost exclusively
expressed by endothelial cells and may act in an autocrine fashion
[16–19]. It is expressed at high levels early during mouse
embryonic development and is strictly associated with the vascular
bed. Prior studies have shown EGFL7 to mediate its angiogenic
effects by interfering with the Notch pathway [20,21]. However,
the role of Egfl7 in vascular development has been complicated by
the presence of the microRNA miR126 within its gene. Thus,
knockout studies of EGFL7 may alter the epigenetic regulation of
angiogenesis by miR126. When Kuhnert et al. [22] generated an
EGFL7 knockout that preserved miR126 expression, they did not
observe vascular abnormalities, casting doubt on the role of
EGFL7 in vascular development. Kuhnert et al. went as far as
stating that the observed phenotype in the prior studies was due to
miR126 deregulation since in their study, targeted disruption of
PLOS ONE | www.plosone.org 1 March 2014 | Volume 9 | Issue 3 | e91849Figure 1. VEGF-induced tube formation is EGFL7 dependent. A, Mouse eye cups of each group were treated with EGFL7 or control siRNA
after embedding them in Matrigel. Samples were cultured in VEGF (25 ng/ml) containing medium. At 3 and 5 days after knockdown of EGFL7, the
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prior non-specific EGFL7-knockdown animals. However, in
zebrafish, morpholino antisense oligonucleotides targeting egfl7
resulted in vascular defects that were rescued by co-injection of
egfl7 mRNA [18]; this indicates that EGFL7 has a defined function
(at least in zebrafish vascular development) that is not being
compensated by other genes [18].
Thus, given that the mouse Egfl7 loss-of-function phenotype and
mechanism of action is still unclear, we wanted to investigate the
role EGFL7 in VEGF tube formation and signaling using an ex vivo
angiogenesis assay.
Materials and Methods
Materials
CD31 antibody, which was used to stain the endothelial cells in
Matrigel, was purchased from Novus Biologicals, Inc. (Littleton,
CO). Secondary antibodies of Alexa Fluor 568 goat anti-rat IgG
was purchased from Invitrogen (Carlsbad, CA). Growth Factor
Reduced Matrigel
TM Matrix (Phenol Red-free) and Cell Recovery
Solution were purchased from BD Pharmingen (San Diego, CA).
Mouse VEGF was purchased from R&D Systems (Minneapolis,
MN). Oligofectamine and Opti-MEM were purchased from Life
Technologies (Grand Island, NY). SiRNA targeting EGFL7 and
control siRNA were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA).
Matrigel Cultures of Freshly Cut Eye Tissue
Eyes were enucleated from 6- to 8-week-old C57BL/6 (B6) mice
and rinsed in PBS (2) supplemented with 5 ml penicillin/
streptomycin (100x) (Invitrogen, Carlsbad, CA). Eye samples
(which contained retina-RPE-choroid-sclera) were excised in a
circle around the optic nerve head using a 1.0-mm skin biopsy
punch (Integra Miltex, Plainsboro, NJ) (Fig. S1). Freshly cut tissue
samples were embedded in Matrigel and grown in 0.5 ml of
Dulbecco’s modified Eagle’s medium (DMEM) (Life Technologies,
Grand Island, NY) with 10% fetal bovine serum in a 24-well plate.
For all experiments, cells were grown at 37uC in a humidified
atmosphere of 5% CO2 and 95% air.
All animal experimental procedures were designed ethically to
conform to both the ARVO Statement for the Use of Animals in
Ophthalmic Vision Research and approved by the Institutional
Animal Care and Use Committee (IACUC) of Massachusetts Eye
and Ear Infirmary.
Immunofluorescence Staining of Matrigel-embedded
Mouse Eye Tissue
Immunofluorescence staining of Matrigel-embedded mouse eye
tissue was performed according to Baker et al. [23]. Briefly, after
the removal of the culture medium, Matrigel-embedded eye tissues
samples were washed in PBS (+). Samples were then fixed in 4%
PFA for 30 min at room temperature, and permeabilized in PBS(+
) supplemented with 0.25% Triton X-100 two times at room
temperature. Nonspecific antibody binding was blocked with 5%
BSA in PBS (+) supplemented with 0.1 ml of 1 M MnCl2 and 1%
Tween-20. Samples were incubated overnight with rat monoclonal
CD31 antibody, 1: 1000 dilution at 4uC. Then, after washing
three times with PBS(2) supplemented with 0.1% Triton X-100,
samples were incubated for 2 hours with Alexa Fluor 568 goat
anti-rat IgG. Samples were then rinsed three times in PBS(2)
before mounting, and images were acquired with Zeiss Axioplan
microscope.
siRNA Transfection
Small interfering RNA (siRNA) transfection was performed
using Oligofectamine according to the protocol of Baker et al.
[23]. After the preparation of solution ‘‘A’’ (2.5 mlo f4 0 mM
siRNA stock in 182.5 ml of Opti-MEM per sample) and solution
‘‘B’’ (3 ml of Oligofectamine reagent in 12 ml of Opti-MEM per
sample), respectively, solution A and B were mixed and placed for
20 min at RT beforehand. And, after Matrigel-embedded mouse
eye tissue of each well was filled with 800 ml Opti-MEM in 24-well
plate, 200 mlo fA +B mixed solution was added to each well to
achieve a final volume of 1 ml. Each sample was incubated
overnight at 37uC and 5% CO2 in the Opti-MEM mixture.
Preparation of Antibody-coated Magnetic Beads for
Endothelial Cell Isolation
Dynabeads sheep anti-rat IgG was washed three times with PBS
containing 0.1% bovine serum albumin (BSA) and then incubated
with rat anti-mouse CD31 monoclonal antibody for 2 hours at
room temperature. Following incubation, beads were washed
three times with PBS containing 0.1% BSA and resuspended in
the same medium.
Isolation of Endothelial Cells
Matrigel-embedded eye tissue samples were treated with Cell
Recovery Solution supplemented with phosphatase and protease
inhibitor mixture for 15 minuts at 4uC, and cells were isolated
using anti CD31-coated Dynabeads.
Real-time Quantitative RT-PCR (qRT-PCR)
Total RNA was harvested from isolated cells using the RNeasy
kit (Qiagen, Valencia, CA), and complementary DNA (cDNA) was
generated with oligo-dT primers and SuperScript Reverse III
Transcriptase (Invitrogen) according to the manufacturer’s
instructions. Real-time PCR was carried out using the following
mouse TaqMan gene-expression assays (Applied Biosystems,
Foster City, CA): CD31 (Mm01242584_m1), a-SMA
(Mm00725412_s1) and beta actin (Mm00607939_s1). All reac-
tions were prepared following the manufacturer’s protocol and
carried out using the StepOne
TM Real-Time PCR System
(Applied Biosystems).
Protein Extraction and Western Blotting
Isolated cells were rinsed in ice-cold Tris-buffered saline and
then lysed with lysis buffer (50 mM Tris-HCl, pH 7.6, 150 mM
NaCl, 5 mM CaCl2, 1% Triton X-100 and 0.02% NaN3)
supplemented with phosphatase and protease inhibitor mixture.
For Western blotting, each group was collected from 12 to 20 of
Matrigel-embedded eye samples. Cell suspensions were incubated
on ice for 10 minutes and centrifuged at 14,000 rpm for 10
minutes at4uC. Supernatants were collected as whole-cell lysates.
Protein concentration was determined by a DC protein assay kit
(Bio-Rad, Hercules, CA). The proteins were separated by
tube length of neovascular from samples was evaluated by immunofluorescence using CD31 antibody. Bar equals 1000 mm. B, ANOVA Statistical
analysis performed to evaluate the area of tube length. (n=6) *, P,0.01. **, P,0.05. NS, not significant. C. At 3, 5 and 7 days after knockdown of
EGFL7, endothelial cells were collected using anti-mouse CD31 antibody-coated magnetic beads (see Figure S4). The amounts of EGFL7 in isolated
cells were examined by Western blotting.
doi:10.1371/journal.pone.0091849.g001
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PLOS ONE | www.plosone.org 3 March 2014 | Volume 9 | Issue 3 | e91849Figure 2. EGFL7 knockdown does not influence VEGFR2 phosphorylation or neuropilin 1 expression. A, Mouse eye cups of each group
were treated with EGFL7 or control siRNA after embedding them in Matrigel. Samples were cultured in VEGF (25 ng/ml) containing medium. At 3
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MD) and transferred to a nitrocellulose membrane (Millipore,
Bedford, MA). The blots were subsequently incubated with
secondary antibodies conjugated to horseradish peroxidase (Cell
Signaling Technologies). The membranes were then developed by
ECL prime (Amersham, Piscataway, NJ, USA). Densitometric
analysis of bands was performed using ImageJ software. Lane-
loading differences were normalized by b-actin.
Total RNA Extraction and miRNA Expression
To identify mir-126 expression in mouse endothelial cells after
the treatment of EGFL7 siRNA, total RNA with mir-126 was
extracted from mouse endothelial cells in the matrigel using
QuantiGene Sample Processing Kit (Affymetrix, Santa Clara, CA)
according to manufacture’s protocol. Following RNA isolation,
miRNA expression was measured using QuantiGene 2.0 Reagent
System (Affymetrix) according to manufacture’s protocol. To
capture mir-126 from samples, the capture plates containing
samples and working probe set (capture extender (CE), label
extender (LE), blocking probe (BL)) were incubated overnight at
55uC61uC for hybridization. After hybridization using the Pre-
Amplifier and Amplifer, the capture plate was hybridized with the
label probe according to manufacture’s protocol. Luminescence
was measured using a microplate luminometer after adding of 2.0
Substrate according to manufacture’s protocol. The probe for
miR126 sequence (ucguaccgugaguaauaaugcg) was purchased from
Affymetrix. The number of each group is 4.
Statistical Analysis
All experiments were repeated a minimum of three times. All
data were expressed as means 6 S.D. Statistical differences were
analyzed by ANOVA test. Differences were considered significant
at P,0.05.
Results
VEGF-induced Tube Formation is EGFL7 Dependent
Similar to aortic ring assay, VEGF application to the Matrigel-
embedded mouse eye cup (Fig. S1) led to dose- and time-
dependent neovessel tube formation from capillary-size vessels
from mice eye cups (Fig. S2A–D). There was a rather linear
response to VEGF from 12 ng/ml to 50 ng/ml. Neovessel
formation was first seen at day 3 and continued to increase over
a week (Fig. S2C–D). To investigate the role of EGFL7 in this
process, loss-of-function experiments were performed using siRNA
against EGFL7. As seen in Figure 1, siRNA knockdown of EGFL7
but not control scrambled siRNA resulted in significant decrease
in tube formation both on day 3 and day 5. Since it is well known
and mir-126 is localized within intron 7 of EGFL7 [24] and that
some prior studies have shown that some of the angiogenic
functions of EGFL7 maybe mediated via interference of its
intronic miR126 we investigate whether EGFL7 knockdown by
siRNA had any effects on the expression of mir-126 or not. As seen
in Fig. S3, we could not observe a significant difference of miR-
126 expression between control and EGFL7 siRNA treatment.
This result indicates that EGFL7 knockdown by siRNA can inhibit
angiogenesis independently of mir-126 levels.
EGFL7 Knockdown does not Influence VEGFR2
Phosphorylation or Neuropilin 1 Expression
VEGF mediates its effects partially through VEGFR2 binding
and phosphorylation as well as via Neuropilin 1 receptor that
enhances VEGF binding to VEGFR2 by up to 6-fold [25]. In
addition, it has been reported that VEGF can induce neuropilin 1
protein expression [26]. To investigate whether changes in
VEGFR2 or neuropilin-1 expression after siRNA knockdown of
EGFL7 are responsible for the observed effects, we purified
endothelial cells from mouse eye cups using anti-mouse CD31
antibody-coatedmagneticbeads(Fig.S4 forenrichmentandpurity
results) and analyzed the endothelial cells for VEGFR2 and
neuropilin 1 via Western blotting. As seen in Fig. 2, EGFL7
knockdown did not influence VEGFR2 phosphorylation or
Neuropilin 1 protein expression, suggesting that EGFL7 mediates
its effects further downstream in VEGF signaling.
EGFL7 Mediates VEGF-induced Activation of Akt and
ERK(1/2)
VEGF induced Akt and ERK activation are thought to be
important mediators of VEGF-driven angiogenesis. To examine
the role of EGFL7 in VEGF driven activation of Akt and ERK,
siRNA knockdown experiments were performed. EGFL7 knock-
down suppressed both phosphorylations of Akt and ERK(1/2) at
day3 and day5 compared to the control siRNA (Fig. 3A,B and C).
Moreover, as the effect of siRNA diminished with the passage of
time (day 3R5R7), so did the effect on Akt and ERK(1/2)
(Fig. 3A, D). These results suggest that EGFL7 is required for
VEGF-induced Akt and ERK(1/2) phosphorylation during
angiogenesis.
Discussion
In the present study, we show that EGFL7 is required for the
angiogenic effects of VEGF using a Matrigel-embedded mouse eye
angiogenesis assay similar to the aortic ring assay and similar to the
mouse eye cup described by Shao et al. [27]. Moreover, we
showed that EGFL7 expression is needed for VEGF-induced
upregulation of phospho-Akt and phospho-ERK(1/2) in endothe-
lial cells for the first time.
EGFL7 is a novel secreted angiogenic factor with several key
differences to the well-known secreted angiogenic molecules,
VEGF and fibroblast growth factor-2, which are mainly produced
by non-endothelial cells. In contrast, EGFL7 is almost exclusively
expressed by the endothelial cells themselves [15–19,28]. EGFL7
is expressed in a highly restricted manner in endothelial cells
during embryonic development, when it plays a role in controlling
the patterning and remodeling of vascular tubes during develop-
mental vascularization [16,17,29,30], and promotes angiogenesis
[31]. EGFL7 expression markedly decreases in endothelial cells in
postnatal life [16], consistent with a role in vascular development.
However, the presence of miR126 within the Egfl7 gene
complicates investigations into its role in vascular development,
because knockout studies of EGFL7 may alter epigenetic
regulation by miR126 as well. When Kuhnert et al. [22] generated
an Egfl7 knockout that preserved miR126 expression, they did not
observe vascular abnormalities, calling into question the role of
EGFL7 in vascular development. They asserted that the observed
days after knockdown of EGFL7, endothelial cells were collected using anti-mouse CD31 antibody-coated magnetic beads (see Figure S4). The
amounts of p-VEGFR2, neuropilin 1 and EGFL7 were examined by Western blotting. B, Densitometry of p-VEGFR2 in panel A. C, Densitometry of
neuropilin 1 in panel A. D, Densitometry of EGFL7 in panel A. ANOVA Statistical analysis performed. (n=3) *, P,0.01. **, P,0.05. NS, not significant. *,
P,0.01. NS, not significant.
doi:10.1371/journal.pone.0091849.g002
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since targeted disruption of miR126, but not EGFL7, led to
phenotypic changes seen in the prior nonspecific EGFL7-
knockdown animals. However, in zebrafish, morpholino antisense
oligonucleotides targeting egfl7 resulted in vascular defects that
were rescued by co-injection of egfl7 mRNA, indicating that egfl7
has a defined function at least in zebrafish vascular development
that is not compensated for by other genes [18]. Our study, using
siRNA technology that targets the messenger RNA, bypasses
interference with the intronic miR126 (see Fig. S3) and supports
the notion that egfl7 has direct angiogenic effects.
Prior studies have shown EGFL7 to mediate its angiogenic
effects by interfering with the Notch pathway [20,21]. In addition
the EGFL7 intronic miR126 [32,33] was shown to promote
angiogenesis by inhibiting protein production of endogenous
VEGF repressors within endothelial.
However, not much is known about the effects of EGFL7 on the
VEGF/VEGFR-2/neuropilin 1 pathway. Neurolipin-1 exists on
the cell membrane of endothelial cells as an isoform-specific
receptor for VEGF and as a co-receptor of VEGFR-2. Though
VEGF selectively up-regulates neuropilin 1 via the VEGFR-2
dependent pathway, Oh et al. indicated endothelial proliferation
stimulated by VEGF was inhibited significantly by antibody
perturbation of neuropilin 1, and selective neuropilin 1 inhibition
suppressed neovascular formation substantially in vivo [26]. When
we examined the effects of EGFL7 siRNA knockdown on VEGF
signaling, we observed no significant effects on VEGFR2
phosphorylation or neuropilin 1 expression (Fig. 2). However,
when we looked further downstream we found that EGFL7 was
required for VEGF-induced activation of the Akt/Erk(1/2)
pathways. Thus, EGFL7 not only has direct angiogenesis effects
mediated by Notch signaling, but also indirect effects through the
VEGF signaling pathway.
In conclusion, using the mouse eye cup ex vivo angiogenesis
assay, we identified EGFL7 as required for VEGF-induced
angiogenesis by facilitating VEGF-induced activation of Akt and
Erk(1/2). EGFL7 may represent a target for diseases with
pathological neovascularization.
Supporting Information
Figure S1 The creation of mouse eye cup and Histologic
characterization of mouse eye cup embedded in Matri-
gel. After the removal of mouse cornea and lens (A), the eye
sample (which contains retina-RPE-choroid-sclera) was excised in
a circle round the optic nerve head using 1.0-mm skin biopsy
punch (B,C and D), and embedded it into Matrigel (E). Schema of
posterior segment of the eye that is used (F). Endothelial cells on
the frozen mouse eye tissue section were immunostained with anti-
CD31 antibody (G.H). The colour was developed using HRP
conjugated secondary antibody and DAB staining. The section
was then counterstained with methyl green.
(TIFF)
Figure S2 Dose and time dependent VEGF induction of
neovascular tube formation from mouse eye cups. A,
After the eye cups were embedded in Matrigel, each concentration
of VEGF (0, 12.5, 25.0, 50.0 ng/ml) was added in the medium. At
10 days after culturing in these concentrations of VEGF-
containing medium, the area of neovascularization from samples
was evaluated by immunofluorescence using CD31 antibody.
Medium was changed at days 3 and 7 after embedding. Bar equals
1000 mm. B, ANOVA Statistical analysis performed to evaluate the
area of tube length (n=6). *, P,0.01. C, After the eye tissue
samples were embedded in Matrigel, tissue samples were cultured
in medium containing 25.0 ng/ml VEGF for 3, 7, or 10 days,. At
each day after culturing in VEGF-containing medium, the area of
Figure 3. EGFL7 mediates VEGF-induced activation of Akt and
ERK(1/2). A, Mouse eye cups of each group were treated with EGFL7 or
control siRNA after embedding them in Matrigel. Samples were cultured
in VEGF (25 ng/ml) containing medium. At 3, 5 and 7 days after
knockdown of EGFL7, endothelial cells were collected using anti-mouse
CD31 antibody-coated magnetic beads. The amounts of (p-)Akt, p-
ERK(1/2), EGFL7 and a-SMA in isolated cells were examined by Western
blotting. B, Densitometry of p-Akt in panel A. C, Densitometry of p-
ERK(1/2) in panel A. D, Densitometry of EGFL7 in panel A. ANOVA
Statistical analysis performed. (n=3) *, P,0.01. **, P,0.05. NS, not
significant. *, P,0.01. **, P,0.05. NS, not significant.
doi:10.1371/journal.pone.0091849.g003
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PLOS ONE | www.plosone.org 6 March 2014 | Volume 9 | Issue 3 | e91849neovascular from samples was evaluated by immunofluorescence
using CD31 antibody. Medium was changed at day 3 and 7 after
embedding. Bar equals 1000 mm. D, ANOVA Statistical analysis
performed to evaluate the area of tube length (n=6). *, P,0.01.
**, P,0.05.
(TIFF)
Figure S3 To identify mir-126 expression in mouse
endothelial cells after the treatment of EGFL7 siRNA,
total RNA with mir-126 was extracted from mouse
endothelial cells in the matrigel using QuantiGene
Sample Processing Kit (Affymetrix, Santa Clara, CA)
according to manufacture’s protocol. Following RNA
isolation, miRNA expression was measured using QuantiGene
2.0 Reagent System (Affymetrix) according to manufacture’s
protocol. To capture mir-126 from samples, the capture plates
containing samples and working probe set (capture extender (CE),
label extender (LE), blocking probe (BL)) were incubated overnight
at 55uC61uC for hybridization. After hybridization using the Pre-
Amplifier and Amplifer, the capture plate was hybridized with the
label probe according to manufacture’s protocol. Luminescence
was measured using a microplate luminometer after adding of 2.0
Substrate according to manufacture’s protocol. (The number of
each group is n=4.).
(TIFF)
Figure S4 The purification of endothelial cells from
Matrigel-embedded mouse eye tissue. A, Mouse eye cups of
each group were cultured for 3 days after embedding in Matrigel.
At 3 days after culturing, each lysate was extracted from the
Matrigel-embedded eye tissue (A) and the isolated endothelial cells
using anti-mouse CD31 antibody-coated magnetuc beads (B). The
amounts of CD31 and a-SMA were examined by Western
blotting. B, Densitometry of a-SMA in panel A. ANOVA Statistical
analysis performed. (n=3) *, P,0.01. C,D, Mouse eye cups of
each group were treated with EGFL7 or control siRNA after
embedding them in Matrigel. Samples were cultured in VEGF
(25 ng/ml) containing medium. At 3, 5, and 7 days after
knockdown of EGFL7, endothelial cells were collected using
anti-mouse CD31 antibody-coated magnetic beads. The purifica-
tion of isolated endothelial cells was evaluated by qRT-PCR. The
expression of a-SMA and CD31 mRNA in control, control siRNA
and EGFL7 siRNA treatment groups were examined by qRT-
PCR in panel C and D, respectively. ANOVA Statistical analysis
performed to evaluate mRNA of aSMA. *, P,0.01.
(TIFF)
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